RecruitingNot a traditional drug phaseobservationalRules rewrite

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate…

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice.

Official registry: https://clinicaltrials.gov/study/NCT07136116 · AbbVie · enrollment listed as 200

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 200 people at 29 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP)

Primary outcome (registry wording): To assess the achievement of clinical remission per Partial Adapted Mayo Score of Risankizumab treatment in participants with moderate to severe Ulcerative Colitis (UC)

Who it is for (from inclusion criteria)

Ages 15 Years to any
The decision to prescribe RZB is made prior to and independently of study participation
Participants who can understand and communicate with the investigator and comply with the requirements of the study, including collection of PRO data using a smart device (i.e., mobile phone) and continued PRO data collection after cessation of RZB
Participants without previous exposure to RZB
Participants who are not currently participating in treatment research (not including non-treatment studies, PMOS, or registry participation)

Who the registry excludes

See who can join

Public study contact (from the registry)

AbbVie GK Clinical Trial Registration Desk

+81-3-4577-1111

abbvie_jpn_info_clingov@abbvie.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

29 listed

Aichi Medical University Hospital /ID# 278155 — Nagakute, Aichi-ken, Japan (recruiting)
Nagoya University Hospital /ID# 278159 — Nagoya, Aichi-ken, Japan (recruiting)
Hirosaki University Hospital /ID# 278153 — Hirosaki, Aomori, Japan (recruiting)
Chiba University Hospital /ID# 277669 — Chiba, Chiba, Japan (recruiting)
Tsujinaka Hospital - Kashiwanoha /ID# 277672 — Kashiwa-shi, Chiba, Japan (recruiting)
Toho University Sakura Medical Center /ID# 277536 — Sakura, Chiba, Japan (recruiting)
Kyushu University Hospital /ID# 278077 — Fukuoka, Fukuoka, Japan (recruiting)
Hiroshima University Hospital /ID# 277542 — Hiroshima, Hiroshima, Japan (recruiting)
Sapporo Medical University Hospital /ID# 277535 — Sapporo, Hokkaido, Japan (recruiting)
Hokkaido University Hospital /ID# 277668 — Sapporo, Hokkaido, Japan (recruiting)
Sapporo Higashi Tokushukai Hospital /ID# 278123 — Sapporo, Hokkaido, Japan (recruiting)
Kobe University Hospital /ID# 278292 — Kobe, Hyōgo, Japan (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingNot a traditional drug phaseHouston, Texas

Not a traditional drug phase: testing Ustekinumab for Crohn Disease

This study wants to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

NCT04372108 · Official ClinicalTrials.gov record · Janssen Scientific Affairs, LLC

RecruitingNot a traditional drug phaseToronto, Ontario

The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Dise…

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies.

NCT06006039 · Official ClinicalTrials.gov record · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

FAQ about this NCT record

Is NCT07136116 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07136116?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07136116?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary